NeuroSense Therapeutics (NRSN) to Release Earnings on Monday

NeuroSense Therapeutics (NASDAQ:NRSN) will likely be releasing its earnings data on Monday, March 24th. Analysts expect NeuroSense Therapeutics to post earnings of ($0.12) per share for the quarter.

NeuroSense Therapeutics (NASDAQ:NRSN) last announced its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) EPS for the quarter.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock opened at $1.07 on Friday. The company has a market cap of $14.62 million, a P/E ratio of -1.67 and a beta of 1.28. NeuroSense Therapeutics has a one year low of $0.51 and a one year high of $2.25. The firm has a fifty day moving average of $1.11 and a two-hundred day moving average of $1.14.

Wall Street Analysts Forecast Growth

Separately, Maxim Group restated a “hold” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 16th.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.